Therapeutic drug monitoring--antiepileptic drugs.

M J Eadie
Author Information
  1. M J Eadie: Department of Medicine, University of Queensland, Brisbane, Australia.

Abstract

AIMS: To provide a brief critical review of the basis and contemporary practice of monitoring the concentrations of antiepileptic drugs in biological fluids.
METHODS: The review is based on literature data and observations from clinical practice.
RESULTS: As experience has accumulated, monitoring of antiepileptic drug concentrations has come to be applied mainly to certain of the drugs when present in whole plasma. For these drugs there is a reasonably established relationship between drug concentrations and biological effects, but attention still needs to be paid to issues such as the timing of the measurements in relation to drug intake, the presence or absence of steady-state conditions, the presence in plasma of active metabolites and possible nonlinear pharmacokinetics of particular agents e.g. phenytoin.
CONCLUSIONS: Plasma antiepileptic drug concentration monitoring is coming to be used in a more thoughtful and critical manner. Lack of adequate knowledge of matters such as the relationship between the plasma concentrations and antiepileptic and toxic effects of the drugs, not only the newer, but also the longer established ones, in particular clinical situations, remains more important than deficiencies in analytical methodology in limiting the clinical usefulness of antiepileptic drug concentration monitoring.

References

  1. J Pharmacol Exp Ther. 1956 Nov;118(3):270-9 [PMID: 13377294]
  2. J Lab Clin Med. 1963 Mar;61:501-7 [PMID: 13979554]
  3. J Forensic Sci. 1966 Oct;11(4):552-9 [PMID: 5972681]
  4. JAMA. 1968 Mar 11;203(11):969-72 [PMID: 5694319]
  5. Circulation. 1968 Aug;38(2):363-74 [PMID: 5666850]
  6. Epilepsia. 1970 Jun;11(2):207-15 [PMID: 5270551]
  7. Res Commun Chem Pathol Pharmacol. 1972 May;3(3):455-66 [PMID: 5034507]
  8. Acta Neurol Scand Suppl. 1973;53:103-8 [PMID: 4519452]
  9. Clin Pharmacol Ther. 1974 Aug;16(2):355-62 [PMID: 4851901]
  10. Clin Pharmacol Ther. 1975 Apr;17(4):433-40 [PMID: 1122684]
  11. Neurology. 1975 Jun;25(6):515-24 [PMID: 805382]
  12. Clin Chem. 1975 Aug;21(9):1323-8 [PMID: 168003]
  13. J Clin Pharmacol. 1976 Jan;16(1):51-9 [PMID: 812890]
  14. Proc Aust Assoc Neurol. 1975;12:61-4 [PMID: 1215397]
  15. Clin Chem. 1976 Jun;22(6):733-8 [PMID: 776449]
  16. Neurology. 1976 Oct;26(10):936-73 [PMID: 986584]
  17. Eur J Clin Pharmacol. 1975 Feb 28;8(2):97-105 [PMID: 786678]
  18. Clin Pharmacokinet. 1976;1(1):52-66 [PMID: 797492]
  19. Neurology. 1977 May;27(5):409-13 [PMID: 16232]
  20. Br J Clin Pharmacol. 1977 Oct;4(5):541-7 [PMID: 911604]
  21. Eur J Clin Pharmacol. 1977 Dec 28;12(6):451-6 [PMID: 598420]
  22. Clin Exp Neurol. 1977;14:172-83 [PMID: 99738]
  23. Clin Chem. 1979 May;25(5):686-91 [PMID: 108033]
  24. Epilepsia. 1979 Aug;20(4):431-6 [PMID: 477634]
  25. Epilepsia. 1979 Dec;20(6):705-10 [PMID: 499116]
  26. Arch Neurol. 1980 Nov;37(11):699-703 [PMID: 7436811]
  27. Epilepsia. 1981 Apr;22(2):185-8 [PMID: 7472305]
  28. Epilepsia. 1982 Apr;23(2):153-62 [PMID: 6804223]
  29. Clin Chem. 1982 Nov;28(11):2278-82 [PMID: 6751601]
  30. Clin Exp Neurol. 1981;18:123-31 [PMID: 6926381]
  31. Hum Toxicol. 1983 Jan;2(1):135-47 [PMID: 6840788]
  32. Epilepsia. 1983 Jun;24(3):330-5 [PMID: 6851964]
  33. Ther Drug Monit. 1983;5(4):461-6 [PMID: 6659017]
  34. Ther Drug Monit. 1984;6(1):35-41 [PMID: 6424278]
  35. Pharm Weekbl Sci. 1984 Apr 27;6(2):91-5 [PMID: 6728640]
  36. Arch Neurol. 1984 Aug;41(8):830-4 [PMID: 6466158]
  37. Ther Drug Monit. 1985;7(1):41-5 [PMID: 3992621]
  38. Ther Drug Monit. 1985;7(1):46-50 [PMID: 3887669]
  39. Ther Drug Monit. 1985;7(3):283-9 [PMID: 4049465]
  40. Arch Neurol. 1986 Mar;43(3):263-5 [PMID: 3947275]
  41. Ther Drug Monit. 1986;8(3):346-51 [PMID: 3529518]
  42. Br Med J (Clin Res Ed). 1987 Mar 21;294(6574):723-4 [PMID: 3105708]
  43. Epilepsia. 1988 Mar-Apr;29(2):129-39 [PMID: 3280304]
  44. Aust N Z J Med. 1987 Dec;17(6):574-9 [PMID: 3128970]
  45. Neurology. 1989 Aug;39(8):1009-10 [PMID: 2761696]
  46. Epilepsy Res. 1990 Jul;6(2):146-54 [PMID: 2117529]
  47. Clin Exp Neurol. 1989;26:141-9 [PMID: 2642124]
  48. Clin Pharmacokinet. 1990 Nov;19(5):341-58 [PMID: 2268985]
  49. Ther Drug Monit. 1991 May;13(3):240-3 [PMID: 1926278]
  50. Epilepsy Res. 1992 Mar;11(1):45-9 [PMID: 1373372]
  51. Clin Chem. 1992 Jun;38(6):808-12 [PMID: 1597006]
  52. Clin Chem. 1993 Sep;39(9):1872-7 [PMID: 8375063]
  53. J Chromatogr. 1993 Jun 23;616(1):39-44 [PMID: 8376491]
  54. Drug Saf. 1993 Sep;9(3):156-84 [PMID: 8240723]
  55. Eur J Clin Pharmacol. 1994;46(6):565-7 [PMID: 7995328]
  56. Ther Drug Monit. 1994 Oct;16(5):458-68 [PMID: 7846743]
  57. Eur J Clin Pharmacol. 1994;47(4):355-60 [PMID: 7875188]
  58. Ther Drug Monit. 1994 Dec;16(6):621-3 [PMID: 7878705]
  59. Clin Exp Neurol. 1993;30:127-36 [PMID: 7712623]
  60. JAMA. 1995 Nov 22-29;274(20):1622-6 [PMID: 7474249]
  61. Epilepsia. 1995;36 Suppl 5:S22-9 [PMID: 8806401]
  62. Epilepsy Res. 1996 Jul;24(3):163-72 [PMID: 8832192]
  63. Pharmacoeconomics. 1997 Apr;11(4):343-9 [PMID: 10166408]
  64. J Pharmacol Exp Ther. 1954 Aug;111(4):425-35 [PMID: 13184405]

MeSH Term

Anticonvulsants
Drug Monitoring
Humans

Chemicals

Anticonvulsants

Word Cloud

Created with Highcharts 10.0.0drugantiepilepticdrugsmonitoringconcentrationsclinicalplasmacriticalreviewpracticebiologicalestablishedrelationshipeffectspresenceparticularconcentrationAIMS:providebriefbasiscontemporaryfluidsMETHODS:basedliteraturedataobservationsRESULTS:experienceaccumulatedcomeappliedmainlycertainpresentwholereasonablyattentionstillneedspaidissuestimingmeasurementsrelationintakeabsencesteady-stateconditionsactivemetabolitespossiblenonlinearpharmacokineticsagentsegphenytoinCONCLUSIONS:PlasmacomingusedthoughtfulmannerLackadequateknowledgematterstoxicneweralsolongeronessituationsremainsimportantdeficienciesanalyticalmethodologylimitingusefulnessTherapeuticmonitoring--antiepileptic

Similar Articles

Cited By